An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan

Giuseppe Mancia, Krishna Korlipara, Peter Van Rossum, Giuseppe Villa, Barry Silvert

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Background: The primary objective of this study was to compare the change from baseline in mean diastolic ambulatory blood pressure (ABP) at 24h post dose (trough measurement) after 8 weeks of treatment with irbesartan or valsartan in subjects with mild-to-moderate hypertension. Secondary objectives included comparing the mean changes from baseline in systolic ABP at trough; 24-h ABP; morning and night-time ABP; self-measured systolic blood pressure (SBP) and diastolic blood pressure (DBP); and office-measured SBP and DBP at trough. Design: After a 3-week, single blind, placebo lead-in period, 426 subjects were randomized to receive either irbesartan 150 mg or valsartan 80 mg for 8 weeks. Methods: Ambulatory blood pressure measurements were obtained at baseline and at week 8. Self-measured morning and evening DBP and SBP readings were obtained at home over a 7-day period at baseline and at week 8. Office-measured seated DBP and SBP measurements were obtained at trough, at baseline, and at week 8. Results: Irbesartan demonstrated significantly greater reductions than valsartan for mean change from baseline in diastolic ABP at trough (-6.73 versus -4.84 mmHg, respectively; P=0.035). Irbesartan produced significantly greater reductions than valsartan for mean systolic ABP at trough (-11.62 versus -7.5 mmHg, respectively; P <0.01) and for mean 24-h diastolic ABP (-6.38 versus -4.82 mmHg, respectively; P=0.023) and systolic ABP (-10.24 versus -7.76mmHg; P <0.01). Irbesartan also produced significantly greater reductions than valsartan for office-measured seated DBP (-10.46 versus 7.28 mmHg, respectively; P <0.01) and SBP (-16.23 versus -9.96 mmHg, respectively; P <0.01) and for self-measured morning DBP (-6.28 versus -3.75 mmHg, respectively; P <0.01) and SBP (- 10.21 versus -6.97 mmHg, respectively; P <0.01). Both drugs were well tolerated. Conclusion: Irbesartan was more effective than valsartan in reducing DBP and SBP at trough and in providing greater overall 24-h blood pressure-lowering efficacy.

Original languageEnglish
Pages (from-to)135-142
Number of pages8
JournalBlood Pressure Monitoring
Volume7
Issue number2
DOIs
Publication statusPublished - Apr 2002

Fingerprint

irbesartan
Valsartan
Ambulatory Blood Pressure Monitoring
Angiotensin Receptor Antagonists
Antihypertensive Agents
Blood Pressure

Keywords

  • Ambulatory blood pressure monitoring
  • Angiotensin II receptor antagonists
  • Irbesartan
  • Valsartan

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan. / Mancia, Giuseppe; Korlipara, Krishna; Van Rossum, Peter; Villa, Giuseppe; Silvert, Barry.

In: Blood Pressure Monitoring, Vol. 7, No. 2, 04.2002, p. 135-142.

Research output: Contribution to journalArticle

Mancia, Giuseppe ; Korlipara, Krishna ; Van Rossum, Peter ; Villa, Giuseppe ; Silvert, Barry. / An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan. In: Blood Pressure Monitoring. 2002 ; Vol. 7, No. 2. pp. 135-142.
@article{98a59b8ee57f45279f35978fdc8fe9a4,
title = "An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan",
abstract = "Background: The primary objective of this study was to compare the change from baseline in mean diastolic ambulatory blood pressure (ABP) at 24h post dose (trough measurement) after 8 weeks of treatment with irbesartan or valsartan in subjects with mild-to-moderate hypertension. Secondary objectives included comparing the mean changes from baseline in systolic ABP at trough; 24-h ABP; morning and night-time ABP; self-measured systolic blood pressure (SBP) and diastolic blood pressure (DBP); and office-measured SBP and DBP at trough. Design: After a 3-week, single blind, placebo lead-in period, 426 subjects were randomized to receive either irbesartan 150 mg or valsartan 80 mg for 8 weeks. Methods: Ambulatory blood pressure measurements were obtained at baseline and at week 8. Self-measured morning and evening DBP and SBP readings were obtained at home over a 7-day period at baseline and at week 8. Office-measured seated DBP and SBP measurements were obtained at trough, at baseline, and at week 8. Results: Irbesartan demonstrated significantly greater reductions than valsartan for mean change from baseline in diastolic ABP at trough (-6.73 versus -4.84 mmHg, respectively; P=0.035). Irbesartan produced significantly greater reductions than valsartan for mean systolic ABP at trough (-11.62 versus -7.5 mmHg, respectively; P <0.01) and for mean 24-h diastolic ABP (-6.38 versus -4.82 mmHg, respectively; P=0.023) and systolic ABP (-10.24 versus -7.76mmHg; P <0.01). Irbesartan also produced significantly greater reductions than valsartan for office-measured seated DBP (-10.46 versus 7.28 mmHg, respectively; P <0.01) and SBP (-16.23 versus -9.96 mmHg, respectively; P <0.01) and for self-measured morning DBP (-6.28 versus -3.75 mmHg, respectively; P <0.01) and SBP (- 10.21 versus -6.97 mmHg, respectively; P <0.01). Both drugs were well tolerated. Conclusion: Irbesartan was more effective than valsartan in reducing DBP and SBP at trough and in providing greater overall 24-h blood pressure-lowering efficacy.",
keywords = "Ambulatory blood pressure monitoring, Angiotensin II receptor antagonists, Irbesartan, Valsartan",
author = "Giuseppe Mancia and Krishna Korlipara and {Van Rossum}, Peter and Giuseppe Villa and Barry Silvert",
year = "2002",
month = "4",
doi = "10.1097/00126097-200204000-00008",
language = "English",
volume = "7",
pages = "135--142",
journal = "Blood Pressure Monitoring",
issn = "1359-5237",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan

AU - Mancia, Giuseppe

AU - Korlipara, Krishna

AU - Van Rossum, Peter

AU - Villa, Giuseppe

AU - Silvert, Barry

PY - 2002/4

Y1 - 2002/4

N2 - Background: The primary objective of this study was to compare the change from baseline in mean diastolic ambulatory blood pressure (ABP) at 24h post dose (trough measurement) after 8 weeks of treatment with irbesartan or valsartan in subjects with mild-to-moderate hypertension. Secondary objectives included comparing the mean changes from baseline in systolic ABP at trough; 24-h ABP; morning and night-time ABP; self-measured systolic blood pressure (SBP) and diastolic blood pressure (DBP); and office-measured SBP and DBP at trough. Design: After a 3-week, single blind, placebo lead-in period, 426 subjects were randomized to receive either irbesartan 150 mg or valsartan 80 mg for 8 weeks. Methods: Ambulatory blood pressure measurements were obtained at baseline and at week 8. Self-measured morning and evening DBP and SBP readings were obtained at home over a 7-day period at baseline and at week 8. Office-measured seated DBP and SBP measurements were obtained at trough, at baseline, and at week 8. Results: Irbesartan demonstrated significantly greater reductions than valsartan for mean change from baseline in diastolic ABP at trough (-6.73 versus -4.84 mmHg, respectively; P=0.035). Irbesartan produced significantly greater reductions than valsartan for mean systolic ABP at trough (-11.62 versus -7.5 mmHg, respectively; P <0.01) and for mean 24-h diastolic ABP (-6.38 versus -4.82 mmHg, respectively; P=0.023) and systolic ABP (-10.24 versus -7.76mmHg; P <0.01). Irbesartan also produced significantly greater reductions than valsartan for office-measured seated DBP (-10.46 versus 7.28 mmHg, respectively; P <0.01) and SBP (-16.23 versus -9.96 mmHg, respectively; P <0.01) and for self-measured morning DBP (-6.28 versus -3.75 mmHg, respectively; P <0.01) and SBP (- 10.21 versus -6.97 mmHg, respectively; P <0.01). Both drugs were well tolerated. Conclusion: Irbesartan was more effective than valsartan in reducing DBP and SBP at trough and in providing greater overall 24-h blood pressure-lowering efficacy.

AB - Background: The primary objective of this study was to compare the change from baseline in mean diastolic ambulatory blood pressure (ABP) at 24h post dose (trough measurement) after 8 weeks of treatment with irbesartan or valsartan in subjects with mild-to-moderate hypertension. Secondary objectives included comparing the mean changes from baseline in systolic ABP at trough; 24-h ABP; morning and night-time ABP; self-measured systolic blood pressure (SBP) and diastolic blood pressure (DBP); and office-measured SBP and DBP at trough. Design: After a 3-week, single blind, placebo lead-in period, 426 subjects were randomized to receive either irbesartan 150 mg or valsartan 80 mg for 8 weeks. Methods: Ambulatory blood pressure measurements were obtained at baseline and at week 8. Self-measured morning and evening DBP and SBP readings were obtained at home over a 7-day period at baseline and at week 8. Office-measured seated DBP and SBP measurements were obtained at trough, at baseline, and at week 8. Results: Irbesartan demonstrated significantly greater reductions than valsartan for mean change from baseline in diastolic ABP at trough (-6.73 versus -4.84 mmHg, respectively; P=0.035). Irbesartan produced significantly greater reductions than valsartan for mean systolic ABP at trough (-11.62 versus -7.5 mmHg, respectively; P <0.01) and for mean 24-h diastolic ABP (-6.38 versus -4.82 mmHg, respectively; P=0.023) and systolic ABP (-10.24 versus -7.76mmHg; P <0.01). Irbesartan also produced significantly greater reductions than valsartan for office-measured seated DBP (-10.46 versus 7.28 mmHg, respectively; P <0.01) and SBP (-16.23 versus -9.96 mmHg, respectively; P <0.01) and for self-measured morning DBP (-6.28 versus -3.75 mmHg, respectively; P <0.01) and SBP (- 10.21 versus -6.97 mmHg, respectively; P <0.01). Both drugs were well tolerated. Conclusion: Irbesartan was more effective than valsartan in reducing DBP and SBP at trough and in providing greater overall 24-h blood pressure-lowering efficacy.

KW - Ambulatory blood pressure monitoring

KW - Angiotensin II receptor antagonists

KW - Irbesartan

KW - Valsartan

UR - http://www.scopus.com/inward/record.url?scp=0036528691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036528691&partnerID=8YFLogxK

U2 - 10.1097/00126097-200204000-00008

DO - 10.1097/00126097-200204000-00008

M3 - Article

VL - 7

SP - 135

EP - 142

JO - Blood Pressure Monitoring

JF - Blood Pressure Monitoring

SN - 1359-5237

IS - 2

ER -